Thanks, Subodh. Revenues in the first quarter of 2024 were $3.1 million, up 39% compared to $2.2 million in the first quarter of 2023. Gross margins in the first quarter of 2024 came in at 49%, compared to 77% in the first quarter of 2023. Revenue and gross margin variability is to be expected at this stage of the company's evolution given the variable nature of contract deliverables and timing with major government agencies. In addition, our project to develop and deliver a 24-cubit quantum computing system to the UK's National Quantum Computing Centre has a lower gross margin profile when compared to some of our other projects. On the expense side, total OpEx in the first quarter of 2024 was $18.1 million, compared to $23.7 million in the same period of the prior year. The year-over-year decrease was primarily due to our February 2023 restructuring and reduction in workforce, a reduction in public company costs as more activities are being brought in-house and savings from R&D related IT systems rationalization. SG&A expense for the three months ended March 31, 2023 included $1.1 million of expense related to the Ampere Forward Agreement, which expired in October 2023. The Ampere Agreement had no impact on our results for the three months ended March 31, 2024. Stock compensation expense for the first quarter of 2024 was $3 million, compared to $1.7 million for the first quarter of 2023. Stock compensation expense was favorably impacted in the first quarter of 2023 by forfeitures related to the February 2023 restructuring and reduction in workforce. Operating loss for the first quarter of 2024 was $16.6 million, compared to an operating loss of $22 million for the same period of 2023. Net loss for the first quarter of 2024 was $20.8 million, or $0.14 per share, compared to a net loss of $23.4 million, or $0.19 per share for the first quarter of 2023. The non-cash change in the fair value of derivative warrant and earn out liabilities negatively impacted our net loss in the first quarter of 2024 by $4.2 million, compared to a negative impact of $1.2 million for the first quarter of 2023. Cash, cash equivalents, and available for sale investments totaled $102.8 million as of March 31, 2024, compared with $99.9 million as of December 31, 2023. On March 15, 2024, we entered into an ATM sales agreement for shares of our common stock having an aggregate offering price of up to $100 million. Year-to-date, through May 9, 2024, we have raised $32.9 million from the sale of 23 million shares under our prior common stock purchase agreement with B. Riley and our current ATM program, including $23.9 million raised in the three months ended March 31, 2024. As disclosed in today's 10-Q filing, we believe that our existing balances of cash, cash equivalents, and marketable security should be sufficient to meet our anticipated operating cash needs until midway through the fourth quarter of 2025 based on our current business plan and expectations and assumptions considering current macroeconomic conditions. Thank you. We would now be happy to answer your questions.